Diabetes sufferers who use a new pill from Bristol-Myers Squibb will want to pay attention to a recent report by the U.S. Food and Drug Administration. The FDA is warning consumers about the health risks associated with a diabetes pill, according to news reports .
U.S. drug reviewers said a new pill from Bristol-Myers Squibb Co and AstraZeneca Plc was effective in treating diabetes, but posed a number of safety risks.
The pill, with the chemical name dapagliflozin, could also be less effective if patients had kidney problems, reviewers from the Food and Drug Administration said in documents released Friday.
In clinical trials, the drug has been linked to a higher number of bladder and breast cancer.
The reviewers also focused on liver injury, bone safety, and urinary and genital infections.
A panel of FDA advisers will review the data on dapagliflozin next Tuesday.
As a Greenville personal injury lawyer I hope that nobody is adversely affected by this product. I urge customers who use this medication to talk to a doctor about the possible health risks. While the Food and Drug Administration hasn’t urged a recall on this product, it still may be dangerous to your health.
If you or a loved one has been injured by medical malpractice, contact a personal injury lawyer in Greenville who can help.
